Avaliação da independência funcional em pacientes com síndrome pós-poliomielite submetidos ao uso de L-Carnitina e Piracetam

• Ano de defesa: 2020
• Autor(a) principal: Helou, Aline Simao [UNIFESP]
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de São Paulo (UNIFESP)
• Palavras-chave em Português: Functionality; Post-Polio Syndrome; L-Carnitine; Piracetam; Functional Independence Scale; Funcionalidade; Síndrome Pós-Poliomielite; L-Carnitina; Escala De Independência Funcional
• Link de acesso: https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=9690995; https://hdl.handle.net/11600/64210

Evaluation of functional independence in patients with Post-Polio Syndrome submitted to the use of L-Carnitine and Piracetam. Introduction: Post-Polio Syndrome is a neurological disease, characterized by the appearance of new weakness and abnormal muscle fatigue, resulting in decreased neuromuscular functions. The MIF (Functional Independence Measure) is an instrument for assessing disability with functional restrictions of varied origin. Each item can be classified in a scale of dependency in 7 levels, being the value 0 corresponding to the total dependence and the value 7 performing tasks independently. Objective: To verify, through the MIF scale, whether patients with the diagnosis of SPP present changes in the aspect of the functionality after the use of L-carnitine + Piracetam. And there are changes in the domain (self-care, transfers and locomotion). Method: Randomized, double-blind, placebo-controlled clinical trial comparing the use of L-carnitine + Piracetam with placebo as adjunctive therapy in the treatment of PPS. The randomization rate will be 2: 1 in favor of the experimental group. A total of 94 patients were selected. After the evaluations, administration of L-carnitine (330 mg) + Piracetam (270 mg) or placebo in capsules was started to be taken 3 oral capsules, 2X per day. The medication will be administered at the visit1 and will correspond to 10 weeks. The MIF test was performed from V1 to V3. Results based on the results, we conclude that there is no statistically significant mean difference between the groups that in all visits, in general and also in the gain. For the gain we could note that Active increased the result on average by 0.155 versus an average reduction of -0.107 Placebo, but this difference is not considered significant. Conclusion: Patients with PPS have deformities installed. Even if the proposed medication helps in the aspect of fatigue, thus improving the willingness to perform its activities, we do not observe functional changes in the activities of daily living.